Free tool
FAERS Monitor: Antivert
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 010721 or its brand name (Antivert, Meclizine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
2,847
Serious
1,381
49% of reports
Hospitalization
688
Death reported
179
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue337
- dizziness295
- nausea280
- headache257
- product dose omission issue235
- pain221
- diarrhoea214
- fall190
- dyspnoea180
- drug ineffective175
- pruritus148
- off label use147
- cough142
- asthenia136
- pain in extremity125
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 7 |
| 2006 | 5 |
| 2007 | 3 |
| 2008 | 1 |
| 2010 | 19 |
| 2011 | 8 |
| 2012 | 34 |
| 2013 | 22 |
| 2014 | 19 |
| 2015 | 22 |
| 2016 | 43 |
| 2017 | 31 |
| 2018 | 54 |
| 2019 | 56 |
| 2020 | 134 |
| 2021 | 215 |
| 2022 | 404 |
| 2023 | 378 |
| 2024 | 449 |
| 2025 | 578 |
| 2026 | 362 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,312 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product dose omission issueSignal | 235 | 5.9 | 5.2 | 966 |
| dizzinessSignal | 295 | 4.4 | 3.9 | 782 |
| fallSignal | 190 | 4.2 | 3.7 | 471 |
| coughSignal | 142 | 3.7 | 3.2 | 286 |
| fatigueSignal | 337 | 3.2 | 2.9 | 526 |
| pain in extremitySignal | 125 | 3.1 | 2.6 | 182 |
| headacheSignal | 257 | 3.0 | 2.7 | 358 |
| pruritusSignal | 148 | 2.8 | 2.4 | 179 |
| astheniaSignal | 136 | 2.7 | 2.3 | 143 |
| painSignal | 221 | 2.7 | 2.3 | 234 |
| nauseaSignal | 280 | 2.6 | 2.3 | 288 |
| diarrhoeaSignal | 214 | 2.4 | 2.2 | 188 |
| dyspnoeaSignal | 180 | 2.3 | 2.0 | 142 |
| off label use | 147 | 1.2 | 1.1 | 7 |
| drug ineffective | 175 | 1.0 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.